Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLS NASDAQ:ASND NYSE:ELAN NASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$41.03$34.89$16.10▼$41.14$5.25B-0.247.54 million shs68.61 million shsASNDAscendis Pharma A/S$247.05$232.68$153.49▼$250.74$15.41B0.41739,020 shs450,896 shsELANElanco Animal Health$21.77+0.2%$23.02$12.40▼$27.72$10.87B1.697.07 million shs5.83 million shsROIVRoivant Sciences$29.96$28.46$10.59▼$32.79$21.44B1.146.30 million shs5.87 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals0.00%0.00%+0.22%+82.60%+135.26%ASNDAscendis Pharma A/S0.00%+2.72%+7.76%+5.15%+52.50%ELANElanco Animal Health0.00%+9.64%-4.35%-11.94%+71.90%ROIVRoivant Sciences0.00%+2.29%+9.30%+7.93%+175.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$41.03$34.89$16.10▼$41.14$5.25B-0.247.54 million shs68.61 million shsASNDAscendis Pharma A/S$247.05$232.68$153.49▼$250.74$15.41B0.41739,020 shs450,896 shsELANElanco Animal Health$21.77+0.2%$23.02$12.40▼$27.72$10.87B1.697.07 million shs5.83 million shsROIVRoivant Sciences$29.96$28.46$10.59▼$32.79$21.44B1.146.30 million shs5.87 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals0.00%0.00%+0.22%+82.60%+135.26%ASNDAscendis Pharma A/S0.00%+2.72%+7.76%+5.15%+52.50%ELANElanco Animal Health0.00%+9.64%-4.35%-11.94%+71.90%ROIVRoivant Sciences0.00%+2.29%+9.30%+7.93%+175.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLSApellis Pharmaceuticals 2.09Hold$35.72-12.94% DownsideASNDAscendis Pharma A/S 3.00Buy$295.3919.57% UpsideELANElanco Animal Health 2.77Moderate Buy$28.2029.55% UpsideROIVRoivant Sciences 2.75Moderate Buy$33.0510.30% UpsideCurrent Analyst Ratings BreakdownLatest ROIV, ASND, APLS, and ELAN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026ROIVRoivant Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/21/2026ROIVRoivant Sciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/21/2026ROIVRoivant Sciences TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $41.005/21/2026ROIVRoivant Sciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $42.005/21/2026ROIVRoivant Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.005/21/2026ROIVRoivant Sciences Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$42.005/18/2026ASNDAscendis Pharma A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$355.005/18/2026ASNDAscendis Pharma A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy5/15/2026ASNDAscendis Pharma A/S EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$329.005/15/2026APLSApellis Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral5/11/2026ELANElanco Animal Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLSApellis Pharmaceuticals$1.11B4.75$0.21 per share196.33$3.24 per share12.66ASNDAscendis Pharma A/S$814.57M18.92N/AN/A$9.16 per share26.97ELANElanco Animal Health$4.72B2.31$2.33 per share9.36$13.01 per share1.67ROIVRoivant Sciences$8.26M2,595.93N/AN/A$7.39 per share4.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLSApellis Pharmaceuticals$22.39M$1.0240.23N/AN/A12.06%39.71%13.20%7/30/2026 (Estimated)ASNDAscendis Pharma A/S-$258M$8.6728.4923.85N/A57.87%N/A-8.37%8/6/2026 (Estimated)ELANElanco Animal Health-$232M-$0.50N/A17.992.34-4.95%7.42%3.66%8/6/2026 (Estimated)ROIVRoivant Sciences-$171.98M-$0.60N/AN/AN/A-3,629.19%-20.54%-19.43%8/10/2026 (Estimated)Latest ROIV, ASND, APLS, and ELAN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026ROIVRoivant Sciences-$0.2893$0.28+$0.5693$0.28$3.41 million$2.52 million5/7/2026Q1 2026APLSApellis Pharmaceuticals-$0.2888$0.15+$0.4388$0.15$208.91 million$268.30 million5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 million5/6/2026Q1 2026ELANElanco Animal Health$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/AELANElanco Animal HealthN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLSApellis Pharmaceuticals0.873.633.16ASNDAscendis Pharma A/S0.791.000.72ELANElanco Animal Health0.602.161.12ROIVRoivant SciencesN/A18.3730.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLSApellis Pharmaceuticals96.29%ASNDAscendis Pharma A/SN/AELANElanco Animal Health97.48%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipAPLSApellis Pharmaceuticals6.50%ASNDAscendis Pharma A/S40.00%ELANElanco Animal Health1.14%ROIVRoivant Sciences10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLSApellis Pharmaceuticals770128.02 million119.70 millionOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableELANElanco Animal Health9,400499.45 million493.76 millionOptionableROIVRoivant Sciences860715.70 million638.41 millionOptionableROIV, ASND, APLS, and ELAN HeadlinesRecent News About These Companies5 High Growth Stocks to Buy and Hold for the Next Decade1 hour ago | insidermonkey.comBlue Owl Capital Holdings LP Sells 725,000 Shares of Roivant Sciences Ltd. $ROIVMay 25 at 3:36 AM | marketbeat.comJefferies Financial Group Inc. Purchases Shares of 3,514,833 Roivant Sciences Ltd. $ROIVMay 24 at 5:51 AM | marketbeat.comEric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) StockMay 23 at 7:50 AM | insidertrades.comAnalysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Roivant Sciences (ROIV)May 22 at 5:52 PM | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Citius Oncology (CTOR)May 22 at 2:50 AM | theglobeandmail.comRoivant Sciences (NASDAQ:ROIV) Posts Earnings Results, Beats Estimates By $0.57 EPSMay 21, 2026 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Q4 2025 Earnings Call TranscriptMay 21, 2026 | insidermonkey.comRoivant Sciences Ltd. 2025 Q4 - Results - Earnings Call PresentationMay 21, 2026 | seekingalpha.comRoivant Sciences (NASDAQ:ROIV) Hits New 52-Week High on Earnings BeatMay 21, 2026 | marketbeat.comRoivant (ROIV) Climbs 15% on Swing to ProfitsMay 20, 2026 | insidermonkey.comRoivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readoutsMay 20, 2026 | seekingalpha.comRoivant Sciences Ltd (ROIV) Q4 2025 Earnings Call Highlights: Strategic Settlements and ...May 20, 2026 | finance.yahoo.comRoivant (ROIV) Climbs 15% on Swing to ProfitsMay 20, 2026 | finance.yahoo.comRoivant Sciences Earnings Call Highlights High-Impact PipelineMay 20, 2026 | tipranks.comRoivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call TranscriptMay 20, 2026 | seekingalpha.comRoivant Shares Climb on Earnings Beat Despite Revenue Shortfall (ROIV)May 20, 2026 | finance.yahoo.com2 Biotech Stocks Are Surging Today Thanks to This Arthritis DrugMay 20, 2026 | barrons.comRoivant Sciences Q4 Earnings Call HighlightsMay 20, 2026 | marketbeat.comRoivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue EstimatesMay 20, 2026 | zacks.comRoivant Sciences: Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business UpdateMay 20, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeROIV, ASND, APLS, and ELAN Company DescriptionsApellis Pharmaceuticals NASDAQ:APLSApellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Ascendis Pharma A/S NASDAQ:ASND$247.05 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$247.18 +0.13 (+0.05%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Elanco Animal Health NYSE:ELAN$21.77 +0.04 (+0.17%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$21.40 -0.36 (-1.67%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.Roivant Sciences NASDAQ:ROIV$29.96 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$30.07 +0.11 (+0.37%) As of 05/22/2026 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
